A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab adjunctive therapy in adult participants with COPD with type 2 inflammation characterized by an eosinophilic phenotype (ENDURA-2)

Principal Investigator

Dr Rob Hallifax

Contact us

Email: samantha.chilcott@ndm.ox.ac.uk

IRAS number

1012603